Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-118 in Plaque Psoriasis
NCT02462070Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Halobetasol propionate 0.05% lotion and tazarotene in plaque psoriasis (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Percentage of Participants With Treatment Success at 8 weeks. Started Aug 2015; status: completed.
02
Drugs
Halobetasol propionate 0.05% lotiontazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02462070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462070.